Ipamorelin: The Complete Research Guide

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed in the late 1990s by Novo Nordisk as part of a program researching selective growth hormone secretagogues (GHS). First described by Johansen et al. in 1998, it was characterized as a highly selective GH-releasing peptide with a cleaner hormonal side-effect profile than earlier compounds in its class.

The compound binds the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by the hunger hormone ghrelin. What separated Ipamorelin from predecessors like GHRP-2 and GHRP-6 was selectivity: where those peptides triggered broad hormonal responses including cortisol and prolactin spikes, Ipamorelin appeared to stimulate GH release without significantly activating those axes, at the doses studied in early trials.

Ipamorelin never reached approved drug status. Novo Nordisk discontinued its development program before phase III trials, and the compound has since circulated primarily in research contexts and through compounding pharmacies. Understanding the evidence requires separating the animal model data (extensive) from the human trial data (sparse).

Research Status

Mixed — predominantly animal models with limited human data.

The bulk of mechanistic data comes from rat and pig studies conducted between 1998 and 2004, many by Novo Nordisk's own team. Human data is limited to early-phase clinical studies focused on GI motility — not the body composition or longevity applications for which it is most widely discussed. There are no published phase III trials and no approved indications.

Mechanism

GHS-R1a Agonism and Pulsatile GH Release

Ipamorelin binds GHS-R1a, a G-protein coupled receptor in the pituitary and hypothalamus, stimulating somatotroph cells to release stored GH in pulses. This mechanism amplifies the body's existing GH pulses driven by endogenous GHRH rather than creating an artificial pattern. This is why Ipamorelin is frequently combined with GHRH analogues like CJC-1295 — the two act on different receptors and appear synergistic on GH pulse amplitude. See the CJC-1295 + Ipamorelin research guide for the combination evidence.

Selectivity for GH Over Cortisol and Prolactin

Johansen et al. (1999) showed in rats that GH-stimulating doses of Ipamorelin did not significantly elevate ACTH, cortisol, or prolactin — contrasting with GHRP-2 and GHRP-6 at comparable doses. Early human pharmacology data supported this selectivity at the specific doses tested. Whether it holds at the higher or more frequent doses used in compounding protocols remains untested.

IGF-1 and Downstream Effects

Like all GH-stimulating compounds, Ipamorelin's downstream tissue effects are primarily mediated through IGF-1, produced in the liver in response to GH. In rat studies, repeated dosing produced sustained IGF-1 elevations and body composition changes consistent with GH axis activation. Human IGF-1 response to sustained Ipamorelin dosing has not been characterized in published trials. Svensson et al. (2000) also found increased cortical bone density and osteoblast markers in rats — a signal not replicated in human trials. Pharmacokinetically, Ipamorelin's plasma half-life is approximately two hours in animal models, with GH peaks at 15–30 minutes post-injection.

What the Human Trials Actually Show

GH Pulse Amplitude

Raun et al. (1998) characterized dose-dependent GH release in healthy male subjects following single subcutaneous doses. GH peaks occurred at 15–30 minutes, substantially above placebo but smaller than GHRP-6 at comparable doses — consistent with partial GHS-R1a agonism. ACTH and cortisol did not rise significantly above baseline, supporting the selectivity data from animal models.

Post-Surgical GI Motility: The Most Developed Human Indication

The clinical indication receiving the most structured investigation was postoperative ileus, pursued because GHS-R1a receptors are expressed throughout the GI tract.

Ejskjaer et al. (2009): A phase II randomized trial of IV Ipamorelin following major abdominal surgery found earlier return of GI function versus placebo — earlier first bowel movement and faster tolerance of oral feeding. Effect size was modest, and Novo Nordisk did not advance to phase III.

Wo et al. (2011): A smaller gastroparesis study found improved gastric emptying on scintigraphy versus placebo. Effect sizes were modest and the trial was not designed for regulatory approval.

These GI motility trials represent the strongest human efficacy evidence for Ipamorelin — for an indication entirely different from the body composition and longevity applications most widely discussed today.

Body Composition: No Published Human RCT Evidence

There are no published, peer-reviewed randomized controlled trials examining Ipamorelin's effects on body composition, muscle mass, fat mass, or sustained IGF-1 in humans. The effects widely cited in compounding pharmacy and longevity clinic contexts are extrapolations from GH axis pharmacology and animal data. This gap is frequently understated in commercial discussions of the compound.

Human Safety Signal

Across the conducted trials, Ipamorelin's safety profile was generally clean — injection site reactions and transient headache were most common, with no serious adverse events attributed to the compound. These were short-term trials not powered for safety endpoints; long-term human safety is uncharacterized.

Ipamorelin vs. GHRP-6: Selectivity Comparison

Molecular Properties

What the Research Doesn't Yet Show

1. Body composition effects in humans. No RCT has tested whether Ipamorelin produces meaningful changes in lean mass or fat mass at clinically used doses. Animal data and GH axis pharmacology support the mechanism; direct human evidence is absent.

2. Optimal human dosing. Dose-response data for sustained IGF-1 elevation in humans is unpublished. Compounding protocols are derived from animal studies and clinical extrapolation, not human dose-finding trials.

3. Long-term safety. No study has followed humans taking Ipamorelin beyond several weeks. Theoretical concerns — insulin sensitivity changes, IGF-1-mediated proliferative risk, pituitary downregulation — have not been evaluated in long-term human trials.

4. Whether selectivity holds at compounding doses. Cortisol and prolactin selectivity was characterized at specific dose ranges. Whether it holds at the higher or more frequent dosing patterns used in optimization protocols is untested.

5. Standalone vs. combination effects. Most current use pairs Ipamorelin with a GHRH analogue. The effects of Ipamorelin alone on human body composition or IGF-1 — separate from a combination protocol — have not been characterized in controlled trials.

Practical Considerations

• Route: Subcutaneous injection is the route used in all human research. Oral bioavailability for peptides this size is negligible without specialized delivery.
• Timing: GH secretion is suppressed postprandially. Research protocols typically administer Ipamorelin fasted — before sleep or well after the last meal — to preserve GH pulse amplitude.
• Frequency: The ~2-hour half-life means most research protocols use 2–3 daily injections to follow natural GH pulsatility rather than a single large dose.
• Regulatory note: Ipamorelin has no FDA-approved indications. U.S. availability has been through 503A/503B compounding pharmacies; regulatory status has shifted and researchers should verify current eligibility before sourcing.

Where It Fits in Research Protocols

Ipamorelin's primary research interest sits within GH axis optimization — adjacent to GH deficiency research but distinct from it, since most optimization-context subjects are not clinically GH-deficient.

• Hormone Optimization — Protocols are typically framed around restoring youthful GH pulse patterns
• Body Composition — Mechanistic basis is established via GH → IGF-1 axis; human efficacy data is extrapolated, not directly demonstrated
• Ipamorelin compound profile — Molecular detail and receptor kinetics
• Hexarelin — Higher-potency GHRP with different selectivity tradeoffs; useful comparison for understanding the potency/selectivity spectrum
• Sermorelin research guide — GHRH analogue with complementary mechanism and more extensive human trial data

The Bottom Line

Ipamorelin is better characterized pharmacologically than many predecessors in the GHS class, and its selectivity profile — minimal cortisol and prolactin response at tested doses — is one of the more credible findings in the peptide research literature. That said, extrapolating from a single-dose pharmacology study to "safe for long-term repeated administration at higher doses" is a step the published evidence cannot support. Researchers and clinicians using Ipamorelin are working substantially ahead of the available human data.

The GI motility trials represent the strongest human efficacy evidence — a modest but real signal in a very different application than body composition or anti-aging. The body composition effects that drive most clinical interest have no published human RCT evidence, and the long-term safety profile is simply unknown.

For research purposes, Ipamorelin is most accurately described as a selective, moderate-potency GH secretagogue with solid animal pharmacology, a limited short-term human safety signal, and no long-term human efficacy data for longevity or body composition endpoints. The mechanistic rationale is sound; the human evidence has not caught up to the clinical interest.

This content is for research and educational purposes only. It is not medical advice, does not constitute a recommendation to use any compound, and should not replace consultation with a qualified healthcare provider. Ipamorelin is not FDA-approved for any indication.